Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Can Billionaire John Griffin’s Small-Cap Picks Beat the Market?

Page 1 of 2

Today, we decided to analyze the profitability of the small-cap equity holdings of billionaire John Griffin‘s $13.8 billion Blue Ridge Capital. To get an overview of Griffin’s stock picking skills in the small-cap category, we backtested the returns of his top five small-cap (companies with a market-cap ranging from $1 billion to $5 billion) holdings between 1999 and 2012. The average value-weighted monthly returns of these holdings stood at 0.97%, compared to an average monthly return of 0.32% for the S&P 500 during this same period. These top five small-cap picks of Griffin also generated a strong average monthly alpha of 0.69%. With that track record of small-cap success in mind, let’s look at Griffin’s top small-caps as of March 31, which are Platform Specialty Products Corp (NYSE:PAH), MGIC Investment Corp. (NYSE:MTG), PBF Energy Inc (NYSE:PBF), Post Holdings Inc (NYSE:POST), and Kate Spade & Co (NYSE:KATE).


Griffin learned the art of investment science from one of the great elder statesmen in the hedge fund industry, serving as second-in-command to veteran investor, Julian Robertson‘s Tiger Management. To get an idea of Griffin’s farsightedness we only need to look at his performance in the trying period of 2007-2009, when financial crises rocked the foundations of the modern financial system. Griffin smoothly sailed through the three year turbulence with an average annual return of 17.83%. The market value of Blue Ridge’s public equity portfolio stood at $8.77 billion at the end of the first quarter. The consumer discretionary and healthcare sectors were the most popular ones of the fund manager, who maintains a diversified portfolio across several sectors.

A reader might question our decision to focus on the small-cap category, considering that its mostly the larger counterparts of these companies that head the portfolios of most hedge funds. The reason for our focus is simple. Our research has shown that in the period between 1999 and 2012 the top small-cap picks of hedge funds outperformed the broader market by nearly one percentage point per month, whereas the top overall picks (mostly large-caps) underperformed by seven basis points per month during the same period. Why pay high fees to own a glut of low-performing stocks when you can invest on your own in hedge funds’ best stock picks? Since its launch in August 2012, Insider Monkey’s small-cap strategy has outperformed the S&P 500 every year, returning over 142% since then, nearly 2.5 times greater than the S&P 500′s returns (read the details here).

Blue Ridge acquired some 46,100 shares of Platform Specialty Products Corp (NYSE:PAH) during the first quarter to take its total stake in the company to 11.0 million shares valued at $282.26 million. The holding represented 3.22% of the fund’s portfolio value. So far this year Platform Specialty Products Corp (NYSE:PAH) is up by nearly 20%, while the Russell 2000, the small-cap index has posted comparatively lackluster returns of about 5% in the same period. The $5.33 billion producer of high technology specialty chemical products beat both the top and bottom line estimates in its financial results for the first quarter. Among over 700 funds that we track, renowned activist Bill Ackman‘s Pershing Square is the largest stockholder of Platform Specialty Products Corp (NYSE:PAH),  owning about 42.74 million shares valued at $1.10 billion.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!